SHL Medical

SHL Medical is a global leader in the design, development, and manufacturing of self-injection drug delivery devices, including autoinjectors and pen injectors. The company serves pharmaceutical and biotechnology partners by providing end-to-end solutions spanning feasibility assessment, device design, development, scale-up, production, and final assembly with labeling and packaging services. SHL Medical's product portfolio includes the Molly series (1.0, 2.25), Maggie series (3.0, 5.0), Reunite, Quanta pen injector, and Elexy innovation platform. The company specializes in enabling patients with chronic conditions such as diabetes and lupus to self-administer injectable treatments, thereby improving treatment outcomes and reducing healthcare system costs. With over 6,000 employees across multiple global locations (Switzerland, Taiwan, Sweden, and the United States), SHL Medical operates manufacturing and R&D facilities that support advanced drug delivery innovation. The company provides device support services, advanced manufacturing solutions, and alliance partnerships with pharmaceutical companies. SHL Medical maintains regulatory compliance standards required for medical device manufacturing and distribution.